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Abstract
Background: Impaired walking capacity is a frequent confinement in Multiple Sclerosis (MS). Patients are affected
by limitations in coordination, walking speed and the distance they may cover. Also abnormal dynamic walking
patterns have been reported, involving continuous deceleration over time. Fampridine (4-aminopyridine), a
potassium channel blocker, may improve walking in MS. The objective of the current study was to comprehensively
examine dynamic walking characteristics and improved walking capacity in MS patients treated with fampridine.
Methods: A sample of N = 35 MS patients (EDSS median: 4) underwent an electronic walking examination prior to
(Time 1), and during treatment with fampridine (Time 2). Patients walked back and forth a distance of 25 ft for a
maximum period of 6 min (6-minute 25-foot-walk). Besides the total distance covered, average speed on the
25-foot distance and on turns was determined separately for each test minute, at Time 1 and Time 2.
Results: Prior to fampridine administration, 27/35 patients (77 %) were able to complete the entire 6 min of
walking, while following the administration, 34/35 patients (97 %) managed to walk for 6 min. In this context,
walking distance considerably increased and treatment was associated with faster walking and turning across all six
test minutes (range of effect sizes: partial eta squared = .34-.72). Importantly, previously reported deceleration across
test minutes was consistently observable at Time 1 and Time 2.
Discussion: Fampridine administration is associated with improved walking speed and endurance. Regardless of a
treatment effect of fampridine, the previously identified, abnormal dynamic walking feature, i.e. the linear decline in
walking speed, may represent a robust feature.
Conclusions: The dynamic walking feature might hence be considered as a candidate for a new outcome measure
in clinical studies involving interventions other than symptomatic treatment, such as immune-modulating
medication.
Trial registration: DRKS00009228 (German Clinical Trials Register). Date obtained: 25.08.2015.
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Background
Multiple sclerosis (MS) is one of the most frequent pro-
gressive neurological diseases. It is often associated with
impaired motor functioning due to an autoimmune re-
sponse which corrupts myelinic sheaths of neurons of
the central nervous system [1]. Among the resulting
motor deficits, impaired walking ability represents a
major confinement, interfering strongly with everyday
life functioning [2–4].
Treatment of walking disability with fampridine
Complementary to immune-modulating medication,
symptomatic treatment may improve motor functioning.
Fampridine (4-aminopyridine) has been shown to be an
effective substance. It may prevent the release of potas-
sium from potassium channels exposed due to the in-
flammatory demyelinating process [5]. Consequently,
disrupted action potential conduction may be partly re-
stored, yielding improvements in motor function and
ambulation (for reviews see [6, 7]).
In their recent systematic review, Jensen et al. [6] re-
port varying response rates to fampridine across studies.
While some negative results with regards to a specific ef-
fect on ambulation and fatigue were reported [8, 9], ana-
lyses of subgroups of responders have predominantly
confirmed positive findings, with response rates ranging
between 35 and 43 % [10–14]. According to Jensen et al.
[6], results across studies are supportive of fampridine
yielding an increase in walking speed of approximately
25 %, i.e. a clinically relevant effect. Convergent evidence
has recently been provided in a placebo-controlled ran-
domized trial, results of which indicated that fampridine
treatment yielded consistent improvements in various
measures addressing mobility and balance throughout a
period of 6 months [15].
The assessment of dynamic walking characteristics in MS
The majority of walking tests implemented in studies
outlined above addressed performance on relatively
short distances, e.g. the 25-foot-walk [16]. Short tests
may be suitable in clinical settings to address general
walking ability, whereas longer tests may provide infor-
mation about symptomatic correlates and underlying
physiologic processes [17–19]. A test of longer duration
commonly used to assess walking disability in MS is
the 6-minute walk, in which walking speed is moni-
tored for 6 min [18, 20–22]. This test may also reveal
impaired dynamic walking features. Burschka et al. [3]
have identified an atypical velocity profile character-
ized by continuous deceleration throughout the test,
relative to healthy controls. MS patients might hence
be characterized by impaired walking dynamics in-
volving a consistent linear decline in walking speed
on the 6-minute walk.
Purpose of the current study
Since improvements in ambulation related to fampridine
treatment have predominantly been addressed by rela-
tively short walking tests, the concurrent body of litera-
ture may be extended by the implementation of tests of
longer duration. Further, the linear deceleration profile
remains to be replicated and it remains to be examined
whether the linear trend shows sufficient temporal sta-
bility. To date, sensitivity of the linear trend to alter-
ations in other clinical parameters remains speculative.
Yet, a replication and an exploration of its properties
might provide initial information on whether it might be
considered as a candidate parameter in intervention
studies. In this context, it appears sensible to examine,
whether the linear trend is consistently observable in pa-
tients treated with fampridine.
In the current study, MS patients completed an auto-
mated 6-minute walking test which required them to
walk back and forth a distance of 25 ft. It was assumed
that (a) prior to administration of fampridine, MS pa-
tients would display overall lower walking speed and
cover a shorter total distance than during treatment with
fampridine. Moreover, it was assumed that (b) the previ-
ously reported linear decline in speed throughout the
test could be consistently replicated at both assessment
points. The latter assumption was derived from findings
reported by Burschka et al. [3], who observed the atyp-
ical linear trend in both, moderately (Expanded Disabil-
ity Status Scale, EDSS >3.5) and mildly disabled patients
(EDSS <4). Subsequently, it was examined whether de-
celeration trends differed across assessment points, in an
exploratory analysis.
Methods
Study design and participants
The current study was approved by the ethical commit-
tee of the University of Bayreuth, Germany. All partici-
pants provided written informed consent. A sample of
35 adult MS patients was recruited in the Deparment of
Neurology, Klinikum Bayreuth GmbH. Patients who
were about to start treatment, or who already received
fampridine, were contacted by a study nurse. Patients
were eligible to participate in the study in case of a con-
firmed MS diagnosis [23], indication for fampridine
treatment, and the ability to continuously walk for at
least 3 min according to self-report. Patients scheduled
for fampridine treatment were tested prior to adminis-
tration of a daily dose of twice 10 mg of Fampyra®
(Time 1) as well as within 1 week following the initial
test (Time 2). Patients who already received fampri-
dine could also participate if they reported to be in-
terested in detailed information about a potential
effect of their treatment. In this case, patients could
pause their daily dose of twice 10 mg of Fampyra®
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and, after a washout period of at least 24 h, be tested
off and on fampridine at Time 1 and Time 2. Sample
characteristics, clinical information and demographics
are displayed in Table 1.
Assessment of walking performance and data analysis
At each of the two assessment points, patients com-
pleted a walking test, which required them to repeatedly
cover a distance of 25 ft throughout a maximal assess-
ment period of 6 min. Patients were instructed to walk
as enduring and fast as possible in context of their walk-
ing disability. An illustration of the general outline of
the walking test is displayed in Fig. 1.
At each end of the 25-foot distance (A), a pole was
placed, 3 ft away from the respective endpoint of the 25-
foot distance (B). Four light sensors were placed parallel
to the 25-foot distance, with which the exact timing of a
patient passing the light sensor was recorded. As walk-
ing speed was continuously monitored throughout the
walking test, the setup yielded the possibility to deter-
mine the average duration on the 25-foot walk (A) and
the average duration for turns at the end of the 25-foot
distance (B). The latter was defined as the time that
passed between leaving and reentering the 25-foot dis-
tance at light sensors 1 and 4, respectively.
In an initial descriptive analysis, it was recorded, how
many minutes of the maximum time of 6 min patients
were able to walk at Time 1 and Time 2. Based on the
previous suggestion, that an improvement in walking
performance of approximately 25 % is of high clinical
relevance [6], the number of patients whose total
distance on the 6-minute walk increased by at least
25 %, or 20 % (two thresholds), was determined.
For the statistical analysis addressing the hypotheses
outlined in the introduction, several parameters were de-
rived for each participant at Time 1 and Time 2:
Total distance. Firstly, as a global parameter, the total
distance covered throughout the test was determined,
including distances (A) and (B).
25-foot-walkspeed. Secondly, the average time required
to cover the 25-foot distance (A) was determined
separately for each test minute. The derivation of
this speed parameter occurred separately for each test
minute, since this yielded the possibility to determine
whether patients showed deceleration on the 25-foot
distance across test minutes. For comparison see
Burschka et al. [3].
Curvespeed. Finally, the average time to walk around the
poles at the end of the 25-foot distance (B) was extracted
as a speed indicator involving the coordinative quality
required to make turns. As was the case for the 25-foot-
walkspeed parameter, mean speed values were calculated
separately for each test minute to evaluate putative
deceleration throughout the walking test.
Statistical analysis
Referring to hypothesis (a), a repeated measures analysis
of variance (ANOVA) involving the within-subjects fac-
tor Time (Time 1 vs. Time 2) was utilized to evaluate a
putative increase in the total distance covered between
respective assessment points, i.e. off vs. on fampridine.
Alterations in 25-foot-walkspeed and Curvespeed were
evaluated with the same ANOVA model.
Additionally, the percentage of patients who were able
to walk throughout the entire 6 min at Time 1 and Time
2 was assessed. As this analysis revealed that all patients
managed to walk at least 4 min at Time 1, the subse-
quent analysis referring to hypothesis (b), was conducted
separately for the first 4 min of the walking test, and for
the entire 6 min of the test. To this end, in case of the
25-foot-walkspeed parameter, the statistical model in-
cluded two within-subjects factors, i.e. Time (Time 1 vs.
Time 2) and Minute (1–4/1–6). The same factors were
included for the analysis of the Curvespeed parameter.
Based on hypothesis (a), a main effect of Time was
expected, reflecting an increase in distance and speed
(25-foot-walkspeed, Curvespeed) from Time 1 to Time 2.
Following hypothesis (b), a significant main effect of
Minute with a linear deceleration trend at Time 1 and
Time 2 was assumed, in line with results of Burschka et al.
[3]. Finally, referring to the exploratory analysis, it was ex-
amined whether a linear trend interaction Time ×Minute
occurred, indicative of a potentially steeper deceleration
slope at Time 1 than at Time 2.
Table 1 Sample description (N = 35)
Demographics
Age M (SD) 54.34 (9.85)
Gender 27 female, 8 male
Clinical information
MS type (N)
Relapsing remitting (RR-MS) 3 (9 %)
Secondary progressive (SP-MS) 26 (74 %)
Primary progressive 6 (17 %)
EDSS score, Mdn (range) 4 (4–7)
Illness duration in years, M (SD) 14.56 (7.95)
Health behavior
Smoking (yes/no) 10/25
Physical activity per week (N) None: 10
1–3 times: 17
4 times: 5
>4 times: 2
Physical activity was defined as any sport/exercise-related activity patients
engaged in on a regular basis, at least once per week
Mdn Median, M Mean, SD Standard deviation
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Results
Prior to administration of fampridine (Time 1), 27/35
patients (77 %) were able to complete the entire 6 min
of walking, while following the administration (Time 2),
34/35 patients (97 %) managed to walk for 6 min. In this
context, 12/34 patients (35 %) showed an increase of at
least 20 % in the total distance covered throughout
the six test minutes, and 8/34 (24 %) showed an increase
of at least 25 %. All 35 patients managed to walk for at
least 4 min at Time 1 and Time 2.
Quantitative analysis: total distance and average speed at
Time 1 and Time 2
The total distance patients covered during the first 4 min
of the walking test (N = 35, Table 2a) and during the entire
6 min (N = 27, Table 2b) significantly increased following
25 feet 
(A) 
3 feet 
(B) 
3 feet 
(B) 
Walking 
Course 
Distance 
Light 
Sensors 
1 2 3 4 
Fig. 1 Illustration of the implemented walking test involving light sensors (1–4) and the examined straight distance (A) and curves (B). See methods
section for details on the derivation of respective walking parameters
Table 2 Alterations in walking performance between Time 1 and Time 2
(a) Minute 1–4 (N = 35) Statistic
Time 1 Time 2 % improvement F p partial eta squared
Total distance (feet)
Mean 758.5 935.2 23 % 49.46 <.001 .59
SD 274.7 253.7
25-foot-walkspeed
Mean 10.21 8.41 18 % 21.25 <.001 .39
SE 0.77 0.52
Curvespeed
Mean 5.55 4.50 19 % 17.34 <.001 .34
SE 0.44 0.30
(b) Minute 1–6 (N = 27) Statistic
Time 1 Time 2 % improvement F p Partial eta squared
Total distance (feet)
Mean 869.0 993.6 14 % 65.82 <.001 .72
SD 200.3 226.0
25-foot-walkspeed
Mean 9.06 7.99 12 % 59.36 <.001 .70
SE 0.60 0.58
Curvespeed
Mean 4.95 4.31 13 % 77.91 <.001 .75
SE 0.35 0.35
Comparison between walking performance at Time 1 (off fampridine) and Time 2 (on fampridine), displayed for test minutes 1–4 (a) and test minutes 1–6 (b).
Mean speed values reflect the duration (in seconds) necessary to cover the 25-foot distance (25-foot-walkspeed) and to circle the poles at the end of the 25-foot
walk distance (Curvespeed), averaged across test minutes 1–4 and 1–6, respectively. Note that the analysis occurred separately for the respective test minutes, due
to the fact that all participants managed to complete the first 4 min of the test at both assessment points (N = 35), whereas data of 27 patients was available for
the entire 6 min at Time 1
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fampridine administration. As displayed in the respective
tables, this increase was characterized by highly significant
main effects of Time, involving large effect sizes. For aver-
age 25-foot-walkspeed and Curvespeed, similar effects were
observed, involving consistent improvements.
Dynamic walking features within walking tests at Time 1
and Time 2
Walking and turning speed significantly decreased across
test minutes. In case of the first four test minutes,
this was reflected by a significant main effect of Minute
on 25-foot-walkspeed [F(3,102) = 13.02, p <.001, partial eta
squared = .28] and on Curvespeed [F(3,102) = 4.85, p = .003,
partial eta squared = .125].
Both main effects involved significant linear trends
[25-foot-walkspeed: F(1,34) = 14.82, p <.001, partial eta
squared = .30; Curvespeed: F(1,34) = 5.96, p = .02, partial
eta squared = .15]. As displayed in Table 3 and Fig. 2, for
minutes 1–4, significant linear deceleration trends on
the 25-foot-walkspeed parameter emerged at Time 1 and
Time 2. In case of the Curvespeed parameter, the linear
deceleration trend did not reach significance at Time 1,
whereas it was significant at Time 2 (Table 3).
When all six test minutes were analyzed at Time 1
and Time 2, a similar pattern of deceleration within re-
spective tests emerged, involving significant main effects
of Minute on 25-foot-walkspeed [F(5,130) = 12.80, p <.001,
partial eta squared = .33] and on Curvespeed [F(5,130) =
7.28, p <.001, partial eta squared = .22]. In both cases,
significant linear trend components were involved
[25-foot-walkspeed: F(1,26) = 18.68, p <.001, partial eta
squared = .42; Curvespeed: F(1,26) = 5.22, p = .001, partial
eta squared = .17], which were observable at Time 1 and
Time 2 (Table 4).
Exploratory analysis: deceleration trend at Time 1 and
Time 2
The exploratory analysis addressing a comparison be-
tween the deceleration trend at Time 1 and Time 2
revealed that the Time ×Minute interaction did not
reach significance, neither in case of the model in-
volving the first four test minutes, nor involving the
entire six test minutes (all p-values >.05).
Discussion
Impaired ambulation is a frequent phenomenon in MS
patients. Besides limitations in walking speed and the
total distance which may be covered, also dynamic walk-
ing features, such as continuous deceleration throughout
longer walking tests have been examined [3]. Fampridine
may exert beneficial effects on walking disability. Never-
theless, the concurrent body of literature may be ex-
tended by examining alterations in walking capacity
related to fampridine on longer walking tests, and with
regards to the atypical linear decline in walking speed.
Improvements in walking capacity and speed
In the current study, fampridine treatment was associ-
ated with improvements in various walking parameters,
including total distance covered and different speed pa-
rameters. Compatible with results of previous work,
fampridine treatment appeared to involve a salient re-
sponse, yielding an increase from 77 % of patients who
were capable of finishing the 6-minute-walking test be-
fore treatment, in comparison to 97 % who were able to
walk for 6 min during treatment. It is noteworthy that
the involved increase in the total distance that patients
were able to cover (23 %, Table 2a) during the first four
test minutes, is congruent with recent estimates, accord-
ing to which fampridine may improve walking capacity
Table 3 Linear deceleration trends during minutes 1–4
Minute Linear trend statistic
Min 1 Min 2 Min 3 Min 4 F p Partial eta squared
25-foot-walkspeed
Time 1 Mean 9.70 10.15 10.33 10.66 12.80 .001 .27
SD 4.02 4.57 4.53 5.25
Time 2 Mean 8.05 8.30 8.60 8.69 12.48 .001 .27
SD 4.02 4.57 4.53 5.25
Curvespeed
Time 1 Mean 5.44 5.54 5.51 5.71 2.11 .16 .06
SD 3.06 2.58 2.43 2.56
Time 2 Mean 4.32 4.50 4.56 4.63 10.08 .003 .23
SD 1.70 1.76 1.81 1.82
Linear deceleration on the speed parameters across minutes 1–4 at Time 1 and Time 2. Mean speed values reflect the average duration (in seconds) necessary to
cover the 25-foot distance (25-foot-walkspeed) and to circle the poles at the end of the 25-foot walk distance (Curvespeed), during respective test minutes 1–4. With
the exception of the Curvespeed parameter at Time 1, patients showed consistent deceleration characterized by significant linear trends. SD Standard deviation
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by 25 % [6]. Moreover, the latter clinical threshold was
surpassed by 24 % of the patients of the current study
on the 6-minute walking test. When a somewhat lower
threshold of 20 % improvement in total distance covered
was applied, 35 % of the sample surpassed that threshold.
Hence, within the boundaries of methodological restric-
tions of the current work, a considerable number of puta-
tive responders could be identified. These findings may be
regarded as generally supportive of the treatment and as-
sessment methodology applied in the current study.
Nevertheless, as outlined in the limitations section in de-
tail, it cannot be ruled out that walking improvements may
have been confounded by a training effect. It also needs to
be considered that in the quantitative analysis of data con-
cerning the total distance covered, alterations were lower
(14 %, Table 2b), when performance on all six test minutes
was analyzed. In sum, these findings also imply consider-
able heterogeneity of alterations in walking performance
across patients and modes of analysis. All further results of
speed parameters hence need to be regarded cautiously,
within the boundaries of these limitations.
The latter reasoning should also be followed when
interpreting the results on walking speed and during
turning (Curvespeed). Highly significant improvements in
coordinative ability required during walking of curves
associated with fampridine treatment might be inter-
preted in favor of fampridine treatment. Nevertheless,
potentially confounding factors, such as heterogeneity of
responsiveness to fampridine within the sample, as well
as a training effect, need to be taken into consideration.
Fig. 2 Improvements in walking speed (a) and curve speed (b) associated with treatment onset of fampridine during test minute 1–4 (N = 35).
The linear deceleration trend, consistently observable at Time 1 and Time 2, was most salient on the 25-foot distance (a; see Table 3 for statistics).
Error bars represent standard errors
Table 4 Linear deceleration trends during minutes 1–6
Minute Linear trend statistic
Min 1 Min 2 Min 3 Min 4 Min 5 Min 6 F p Partial eta squared
25-foot-walkspeed
Time 1 Mean 8.70 8.88 9.02 9.19 9.37 9.19 12.66 .001 .42
SD 3.16 3.02 3.04 3.31 3.41 2.93
Time 2 Mean 7.65 7.84 8.05 8.09 8.19 8.10 12.43 .002 .32
SD 2.71 2.71 3.19 3.21 3.27 3.16
Curvespeed
Time 1 Mean 4.75 4.90 4.92 5.04 5.10 4.96 5.22 .031 .17
SD 1.88 1.76 1.86 1.86 1.90 1.80
Time 2 Mean 4.11 4.23 4.30 4.35 4.39 4.49 8.82 .006 .25
SD 1.67 1.63 1.77 1.77 1.87 2.30
Linear deceleration on the speed parameters across minutes 1–6 at Time 1 and Time 2. Mean speed values reflect the average duration (in seconds) necessary to
cover the 25-foot distance (25-foot-walkspeed) and to circle the poles at the end of the 25-foot walk distance (Curvespeed), during respective test minutes 1–6. SD
Standard deviation
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Dynamic walking features
As Burschka et al. [3] have noted, performance on the
6-minute-walk may reveal information about atypical
dynamic walking features in MS. In the current study,
linear deceleration trends were observed in case of 25-
foot-walkspeed and Curvespeed, at both assessment
points, when patients were off and on fampridine. With
the only exception of performance during the first four
test minutes at Time 1, the linear deceleration trend
was consistently observed. Based on findings reported
by Burschka et al. [3], according to which deceleration
in MS is atypical, relative to performance of healthy in-
dividuals, this implies that the linear trend might repre-
sent a candidate for a new marker of walking disability.
Importantly, sensitivity of the linear trend to alterations
in other clinical parameters remains speculative. How-
ever, in context of this basic methodological study, it is
noteworthy that the linear trend appeared particularly
robust in case of straight distances (25-foot-walkspeed).
It may also be detected for walking characteristics involv-
ing coordinative qualities (Curvespeed). To our knowledge,
the current work represents the first replication of
findings reported by Burschka et al. [3]. Keeping the
above-mentioned, general limitations of the current
study in mind, the current results allow the suggestion
that the linear deceleration trend may be explored as a
candidate clinical marker in MS in future studies.
Limitations
While the current findings are compatible with a puta-
tive treatment effect of fampridine and are promising
with regards to the feasibility of the linear deceleration
trend as a candidate for an outcome measure in future
clinical studies, results need to be interpreted in the con-
text of several limitations. Firstly, it needs to be pointed
out that the current design did not involve a control
group. Conceptually, without such a group, beneficial al-
terations in walking behavior, as observed in the current
study, cannot be attributed to onset of fampridine treat-
ment directly. Given the extensive body of literature in
strong support of such an effect of fampridine [5], and
the methodological emphasis of the current work, this
limitation might not be critical. Nevertheless, the related,
potentially confounding factor of a training effect on the
walking test, as well as heterogeneity of assumed respon-
siveness to fampridine treatment and a small sample size
make a careful interpretation of the results necessary.
Conclusions
Within the boundaries of these limitations, the current
study provides new information on the usefulness of an
automated 6-minute 25-foot walking test for the detec-
tion of beneficial alterations in walking capacity and
speed associated with fampridine treatment. Further, it
provides the first replication of previous findings refer-
ring to the detection of the linear deceleration trend in
MS patients in context of an intervention study. Based
on the latter, the linear deceleration trend may be sug-
gested as a candidate for a marker in the evaluation of
walking performance in future studies.
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